

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended December 31, 2021 and nine month period ended December 31, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



# **S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

## **Other matters**


5. The Statement includes the results for the quarter ended December 31, 2020 and nine month period ended December 31, 2020 as reported in these Unaudited Financial Results have been prepared solely based on the information compiled by the management and have not been subject to audit or review.

Our conclusion on the Statement is not modified in respect of this matter.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

ICAI Firm registration number: 101049W/E300004



per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 22102328ABCXHN6818

Hyderabad



February 10, 2022



**Statement of Unaudited Standalone Financial Results for the Quarter and Nine months period ended 31 December 2021**

|    |   | (Rupees in millions) |                 |                             |                          |                             |                 |
|----|---|----------------------|-----------------|-----------------------------|--------------------------|-----------------------------|-----------------|
|    |   | Quarter Ended        |                 |                             | Nine months period ended |                             | Year ended      |
|    |   | 31-Dec-21            | 30-Sep-21       | 31-Dec-20                   | 31-Dec-21                | 31-Dec-20                   | 31-Mar-21       |
|    |   | (Unaudited)          | (Unaudited)     | (Unaudited)<br>Refer Note 2 | (Unaudited)              | (Unaudited)<br>Refer Note 2 | (Audited)       |
| 1  | <b>Income</b>   |                      |                 |                             |                          |                             |                 |
|    | (a) Revenue from operations   | 2,731.93             | 2,841.73        | 2,541.21                    | 8,888.80                 | 6,760.60                    | 9,326.89        |
|    | (b) Other income  | 31.04                | 93.38           | 3.14                        | 164.59                   | 59.96                       | 96.15           |
|    | <b>Total Income</b>   | <b>2,762.97</b>      | <b>2,935.11</b> | <b>2,544.35</b>             | <b>9,053.39</b>          | <b>6,820.56</b>             | <b>9,423.04</b> |
| 2  | <b>Expenses</b>   |                      |                 |                             |                          |                             |                 |
|    | (a) Purchase of medical consumables, drugs and surgical instruments                             | 577.75               | 618.20          | 492.40                      | 2,060.72                 | 1,418.41                    | 1,959.62        |
|    | (b) Decrease / (increase) in inventories of medical consumables, drugs and surgical instruments | (2.30)               | (14.59)         | 11.82                       | (72.77)                  | 55.09                       | 52.34           |
|    | (c) Employee benefits expense   | 405.60               | 413.23          | 428.61                      | 1,311.03                 | 1,091.19                    | 1,470.36        |
|    | (d) Other expenses  | 763.21               | 844.03          | 821.59                      | 2,510.33                 | 1,999.74                    | 2,804.28        |
|    | (e) Finance cost  | 6.19                 | 10.75           | 43.27                       | 39.43                    | 116.75                      | 147.83          |
|    | (f) Depreciation and amortisation expense   | 114.12               | 114.20          | 128.65                      | 335.68                   | 340.47                      | 445.98          |
|    | <b>Total Expenses</b>   | <b>1,864.57</b>      | <b>1,985.82</b> | <b>1,926.34</b>             | <b>6,184.42</b>          | <b>5,021.65</b>             | <b>6,880.41</b> |
| 3  | <b>Profit before tax (1-2)</b>  | <b>898.40</b>        | <b>949.29</b>   | <b>618.01</b>               | <b>2,868.97</b>          | <b>1,798.91</b>             | <b>2,542.63</b> |
| 4  | <b>Tax expense</b>  |                      |                 |                             |                          |                             |                 |
|    | (a) Current tax   | 223.77               | 243.71          | 154.45                      | 731.02                   | 463.34                      | 668.12          |
|    | (b) Deferred tax charge/(credit)  | 4.69                 | (7.48)          | (12.08)                     | (6.67)                   | (9.59)                      | (1.64)          |
|    | (c) Adjustment of tax relating to earlier periods   | -                    | -               | -                           | -                        | (10.34)                     | (10.34)         |
|    | <b>Total tax expenses</b>   | <b>228.46</b>        | <b>236.23</b>   | <b>142.37</b>               | <b>724.35</b>            | <b>443.41</b>               | <b>656.14</b>   |
| 5  | <b>Profit for the period/year (3-4)</b>   | <b>669.94</b>        | <b>713.06</b>   | <b>475.64</b>               | <b>2,144.62</b>          | <b>1,355.50</b>             | <b>1,886.49</b> |
| 6  | <b>Other comprehensive income</b>   |                      |                 |                             |                          |                             |                 |
|    | Items that will not be reclassified subsequently to statement of profit and loss                |                      |                 |                             |                          |                             |                 |
|    | - Re-measurement loss on defined benefit plans  | (4.56)               | (7.51)          | (11.15)                     | (13.67)                  | (14.35)                     | (6.40)          |
|    | - Income tax effect   | 1.15                 | 1.89            | 2.80                        | 3.44                     | 3.61                        | 1.61            |
|    | <b>Other comprehensive income, net of tax</b>   | <b>(3.41)</b>        | <b>(5.62)</b>   | <b>(8.35)</b>               | <b>(10.23)</b>           | <b>(10.74)</b>              | <b>(4.79)</b>   |
| 7  | <b>Total comprehensive income (5+6)</b>   | <b>666.53</b>        | <b>707.44</b>   | <b>467.29</b>               | <b>2,134.39</b>          | <b>1,344.76</b>             | <b>1,881.70</b> |
| 8  | <b>Paid up equity share capital (face value of Rs.10 each)</b>                                  |                      |                 |                             |                          |                             | 775.93          |
| 9  | <b>Other Equity</b>   |                      |                 |                             |                          |                             | 8,297.30        |
| 10 | <b>Earnings per share (of Rs.10 each) : (not annualised for the quarter ended)</b>              |                      |                 |                             |                          |                             |                 |
|    | (a) Basic (Rs.)   | 8.37                 | 8.91            | 6.39                        | 28.32                    | 18.20                       | 25.20           |
|    | (b) Diluted (Rs.)   | 8.37                 | 8.91            | 6.28                        | 28.32                    | 17.91                       | 24.77           |

*[Handwritten signature]*



**Notes:**

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Standalone Financial Results for the quarter and nine months period ended 31 December 2021 ("Unaudited Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 February 2022 and have been subject to a limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Unaudited Standalone financial results for the quarter and nine months period ended 31 December 2020, have not been subject to an audit or review by our statutory auditors. However, the management has exercised necessary due diligence to ensure that the Unaudited Standalone financial results for these periods provide a true and fair view of the Company's affairs.
- 3 The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 4 The Company has completed Initial Public Offer ("IPO") of 25,995,042 Equity Shares of the face value of Rs. 10/- each at an issue price of Rs. 825/- per Equity Share, comprising offer for sale of 23,560,538 shares by Selling Shareholders and fresh issue of 2,434,504 shares. The Equity Shares of the Company were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on 28 June 2021.
- 5 The utilisation of the net IPO proceeds is summarised below:


| Particulars  | Objects of the issue as per prospectus * | Utilisation upto 31 December 2021 | Unutilised amount as on 31 December 2021 |
|--|--|-----------------------------------|--|
| Repayment/pre-payment, in full or part, of certain borrowings availed by our Company and by our Subsidiaries | 1,500.00                                 | 1,500.00                          | -  |
| General Corporate Purpose  | 416.60                                   | 416.60                            | -  |
| <b>Total</b>   | <b>1,916.60</b>                          | <b>1,916.60</b>                   | <b>-</b>                                 |



\* net of Offer expenses to the extent applicable to the Fresh Issue.

- 6 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.
- 7 The Company operates in one single reportable business segment- "Medical and Healthcare services".
- 8 The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Company is closely monitoring the impact of the pandemic on all aspects of its business, including how it will impact its employees, vendors and business partners. The Company based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact. Based on the current estimates, the Company expects to fully recover the carrying amount of assets, and does not foresee any material adverse impact on its operations. As the outbreak continues to evolve, the Company will continue to closely monitor any material changes to future economic condition.
- 9 The Company has entered into a share purchase agreement ('SPA') and shareholders agreement ('SHA') dated 27 October 2021, with the existing promoter and certain other shareholders of Sarvejana Healthcare Private Limited ('Sunshine Hospitals') to acquire 51.07% of the equity share capital of the Sunshine Hospitals (as a combination of fully paid shares and partly paid up shares, which shall be fully paid up by April 2022, based on agreed schedule). The Sunshine Hospitals is engaged in the healthcare industry. The said acquisition is subject to the fulfillment of various terms and conditions as specified in the SPA and SHA.
- 10 The previous periods numbers have been regrouped/rearranged wherever necessary to conform the current period presentation.
- 11 The above Unaudited Standalone Financial Results of the Company are available on the Company's website [www.kimshospitals.com](http://www.kimshospitals.com) and also on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.

Hyderabad  
10 February 2022

For and on behalf of the Board  
Krishna Institute of Medical Sciences Limited

  
Dr. B Bhaskara Rao  
Managing Director  
DIN: 00008985





**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its joint venture for the quarter ended December 31, 2021 and nine month period ended December 31, 2021 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.



4. The Statement includes the results of the following entities:

| S.no. | Entity   | Relationship    |
|-------|--|-----------------|
| 1     | Krishna Institute of Medical Sciences Limited            | Holding Company |
| 2     | Arunodaya Hospitals Private Limited                      | Subsidiary      |
| 3     | KIMS Hospital Enterprises Private Limited                | Subsidiary      |
| 4     | Iconkrishi Institute of Medical Sciences Private Limited | Subsidiary      |
| 5     | Saveera Institute of Medical Sciences Private Limited    | Subsidiary      |
| 6     | KIMS Hospital Kurnool Private Limited                    | Subsidiary      |
| 7     | KIMS Hospitals Private Limited                           | Subsidiary      |
| 8     | KIMS Swastha Private Limited                             | Subsidiary      |
| 9     | KIMS Cuddles Private Limited*                            | Subsidiary      |
| 10    | KIMS Hospital Bengaluru Private Limited                  | Subsidiary      |
| 11    | Sarvejana Healthcare Private Limited**                   | Joint venture   |

\* the subsidiary has been struck off and dissolved on November 30, 2021

\*\* w.e.f October 27, 2021


5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

#### Other matters

6. The accompanying Statement includes the unaudited interim financial results and other financial information in respect of:
- Four subsidiaries, whose unaudited interim financial results include total revenues of Rs Nil, total net loss after tax of Rs. 0.97 million and 2.70 million, total comprehensive loss of Rs. 0.97 million and 2.70 million for the quarter ended December 31, 2021 and nine month period ended December 31, 2021 respectively, as considered in the Statement which have been reviewed by their respective independent auditors.
  - One joint venture, whose unaudited interim financial results include Group's share of net profit of Rs. 19.66 million and Rs. 19.66 million and Group's share of total comprehensive income of Rs. 19.66 million and Rs. 19.66 million for the quarter ended December 31, 2021 and for the period from October 27, 2021 to December 31, 2021 respectively, as considered in the Statement whose interim financial results, other financial information have been reviewed by their respective independent auditor.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.



# **S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants


7. The Statement includes the results for the quarter ended December 31, 2020 as reported in these unaudited consolidated Financial Results have been prepared solely based on the information compiled by the management and have not been subject to audit or review.

Our conclusion on the Statement is not modified in respect of this matter.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

ICAI Firm registration number: 101049W/E300004



**per Navneet Rai Kabra**

Partner

Membership No.: 102328

UDIN: 22102328ABCYDY3170



Place: Hyderabad

Date: February 10, 2022



**Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months period ended 31 December 2021**

|    |   | (Rupees in millions) |                 |                             |                          |                 |                  |
|----|---|----------------------|-----------------|-----------------------------|--------------------------|-----------------|------------------|
|    |   | Quarter Ended        |                 |                             | Nine months period ended |                 | Year ended       |
|    |   | 31-Dec-21            | 30-Sep-21       | 31-Dec-20                   | 31-Dec-21                | 31-Dec-20       | 31-Mar-21        |
|    |   | (Unaudited)          | (Unaudited)     | (Unaudited)<br>Refer Note 2 | (Unaudited)              | (Audited)       | (Audited)        |
| 1  | <b>Income</b>   |                      |                 |                             |                          |                 |                  |
|    | (a) Revenue from operations   | 3,935.68             | 4,117.40        | 3,606.65                    | 12,784.87                | 9,713.99        | 13,299.37        |
|    | (b) Other income  | 23.92                | 54.06           | 0.85                        | 120.71                   | 59.78           | 101.65           |
|    | <b>Total Income</b>   | <b>3,959.60</b>      | <b>4,171.46</b> | <b>3,607.50</b>             | <b>12,905.58</b>         | <b>9,773.77</b> | <b>13,401.02</b> |
| 2  | <b>Expenses</b>   |                      |                 |                             |                          |                 |                  |
|    | (a) Purchase of medical consumables, drugs and surgical instruments                             | 822.72               | 873.95          | 700.60                      | 2,889.69                 | 2,052.85        | 2,826.39         |
|    | (b) Decrease / (increase) in inventories of medical consumables, drugs and surgical instruments | (0.92)               | (18.79)         | 21.95                       | (89.31)                  | 63.56           | 62.92            |
|    | (c) Employee benefits expense   | 610.40               | 635.04          | 619.27                      | 1,970.57                 | 1,638.06        | 2,202.09         |
|    | (d) Other expenses  | 1,205.87             | 1,339.41        | 1,334.52                    | 3,991.84                 | 3,259.48        | 4,499.14         |
|    | (e) Finance cost  | 29.65                | 28.87           | 90.52                       | 121.74                   | 250.89          | 324.97           |
|    | (f) Depreciation and amortisation expense   | 188.08               | 181.40          | 195.46                      | 540.36                   | 528.98          | 695.36           |
|    | <b>Total Expenses</b>   | <b>2,855.80</b>      | <b>3,039.88</b> | <b>2,962.32</b>             | <b>9,424.89</b>          | <b>7,793.82</b> | <b>10,610.87</b> |
| 3  | <b>Profit before share of profit of Joint Venture and tax (1-2)</b>                             | <b>1,103.80</b>      | <b>1,131.58</b> | <b>645.18</b>               | <b>3,480.69</b>          | <b>1,979.95</b> | <b>2,790.15</b>  |
| 4  | <b>Share of Profit of Joint Venture (refer note 9)</b>  | 19.66                | -               | -                           | 19.66                    | -               | -                |
| 5  | <b>Profit before tax (3+4)</b>  | <b>1,123.46</b>      | <b>1,131.58</b> | <b>645.18</b>               | <b>3,500.35</b>          | <b>1,979.95</b> | <b>2,790.15</b>  |
| 6  | <b>Tax expense</b>  |                      |                 |                             |                          |                 |                  |
|    | (a) Current tax   | 277.30               | 299.66          | 176.63                      | 915.03                   | 545.02          | 778.39           |
|    | (b) Deferred tax (credit)/charge  | 4.29                 | (10.62)         | (8.61)                      | (19.39)                  | (23.02)         | (33.03)          |
|    | (c) Adjustment of tax relating to earlier periods   | -                    | -               | (0.63)                      | -                        | (10.63)         | (10.00)          |
|    | <b>Total tax expenses (6)</b>   | <b>281.59</b>        | <b>289.04</b>   | <b>167.39</b>               | <b>895.64</b>            | <b>511.37</b>   | <b>735.36</b>    |
| 7  | <b>Profit for the period/year (5-6)</b>   | <b>841.87</b>        | <b>842.54</b>   | <b>477.79</b>               | <b>2,604.71</b>          | <b>1,468.58</b> | <b>2,054.79</b>  |
|    | <b>Attributable to:</b>   |                      |                 |                             |                          |                 |                  |
|    | Owners of the company   | 811.75               | 817.17          | 487.91                      | 2,519.97                 | 1,434.17        | 2,012.19         |
|    | Non controlling interests   | 30.12                | 25.37           | (10.12)                     | 84.74                    | 34.41           | 42.60            |
| 8  | <b>Other comprehensive income</b>   |                      |                 |                             |                          |                 |                  |
|    | Items that will not be reclassified subsequently to statement of profit and loss                |                      |                 |                             |                          |                 |                  |
|    | - Re-measurement loss on defined benefit plans  | (4.57)               | (10.44)         | (12.23)                     | (16.48)                  | (15.37)         | (6.28)           |
|    | - Income tax effect   | 1.15                 | 2.68            | 3.13                        | 4.21                     | 3.93            | 1.64             |
|    | <b>Other comprehensive income, net of tax</b>   | <b>(3.42)</b>        | <b>(7.76)</b>   | <b>(9.10)</b>               | <b>(12.27)</b>           | <b>(11.44)</b>  | <b>(4.64)</b>    |
|    | <b>Other comprehensive income/(Loss) for the period/year:</b>                                   |                      |                 |                             |                          |                 |                  |
|    | <b>Attributable to:</b>   |                      |                 |                             |                          |                 |                  |
|    | Owners of the company   | (3.04)               | (6.99)          | (8.94)                      | (11.60)                  | (11.40)         | (4.98)           |
|    | Non controlling interests   | (0.38)               | (0.77)          | (0.16)                      | (0.67)                   | (0.04)          | 0.34             |
|    | <b>Other comprehensive income/(Loss)</b>  | <b>(3.42)</b>        | <b>(7.76)</b>   | <b>(9.10)</b>               | <b>(12.27)</b>           | <b>(11.44)</b>  | <b>(4.64)</b>    |
| 9  | <b>Total comprehensive income (7+8)</b>   |                      |                 |                             |                          |                 |                  |
|    | Owners of the company   | 808.71               | 810.18          | 478.97                      | 2,508.37                 | 1,422.77        | 2,007.21         |
|    | Non controlling interests   | 29.74                | 24.60           | (10.28)                     | 84.07                    | 34.37           | 42.94            |
|    | <b>Total comprehensive income</b>   | <b>838.45</b>        | <b>834.78</b>   | <b>468.69</b>               | <b>2,592.44</b>          | <b>1,457.14</b> | <b>2,050.15</b>  |
| 10 | <b>Paid up equity share capital (face value of Rs.10 each)</b>                                  |                      |                 |                             |                          |                 |                  |
| 11 | <b>Other Equity</b>   |                      |                 |                             |                          |                 | 775.93           |
| 12 | <b>Earnings per share (of Rs.10 each): (not annualised)</b>                                     |                      |                 |                             |                          |                 | 7,861.41         |
|    | (a) Basic (Rs.)   | 10.14                | 10.34           | 6.55                        | 33.27                    | 19.25           | 26.87            |
|    | (b) Diluted (Rs.)   | 10.14                | 10.34           | 6.45                        | 33.27                    | 18.95           | 26.42            |





**Notes:**


- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Consolidated Financial Results for the quarter and nine months period ended 31 December 2021 ("Unaudited Consolidated Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 February 2022 and have been subject to a limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Unaudited Consolidated financial results for the quarter ended 31 December 2020, have not been subject to an audit or review by our statutory auditors. However, the management has exercised necessary due diligence to ensure that the Unaudited Consolidated financial results for these periods provide a true and fair view of the Group's affairs.
- 3 The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 4 The Company has completed Initial Public Offer ("IPO") of 25,995,042 Equity Shares of the face value of Rs. 10/- each at an issue price of Rs. 825/- per Equity Share, comprising offer for sale of 23,560,538 shares by Selling Shareholders and fresh issue of 2,434,504 shares. The Equity Shares of the Company were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on 28 June 2021.
- 5 The utilisation of the net IPO proceeds is summarised below:

| Particulars  | Objects of the issue as per prospectus * | Utilisation upto 31 December 2021 | Unutilised amount as on 31 December 2021 |
|--|--|-----------------------------------|--|
| Repayment/pre-payment, in full or part, of certain borrowings availed by our | 1,500.00                                 | 1,500.00                          | -  |
| General Corporate Purpose  | 416.60                                   | 416.60                            | -  |
| <b>Total</b>   | <b>1,916.60</b>                          | <b>1,916.60</b>                   | <b>-</b>                                 |

\* net of Offer expenses to the extent applicable to the Fresh Issue.

- 6 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.
- 7 The Company operates in one single reportable business segment- "Medical and Healthcare services".
- 8 The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Company is closely monitoring the impact of the pandemic on all aspects of its business, including how it will impact its employees, vendors and business partners. The Company based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact. Based on the current estimates, the Company expects to fully recover the carrying amount of assets, and does not foresee any material adverse impact on its operations. As the outbreak continues to evolve, the Company will continue to closely monitor any material changes to future economic condition.
- 9 The Company has entered into a share purchase agreement ('SPA') and shareholders agreement ('SHA') dated 27 October 2021, with the existing promoter and certain other shareholders of Sarvejana Healthcare Private Limited ('Sunshine Hospitals') to acquire 51.07% of the equity share capital of the Sunshine Hospitals (as a combination of fully paid shares and partly paid up shares, which shall be fully paid up by April 2022, based on agreed schedule). The Sunshine Hospitals is engaged in the healthcare industry. The said acquisition is subject to the fulfillment of various terms and conditions as specified in the SPA and SHA.
- 10 The previous periods numbers have been regrouped/rearranged wherever necessary to conform the current period presentation.
- 11 The above Unaudited Consolidated Financial Results of the Group are available on the Company's website [www.kimshospitals.com](http://www.kimshospitals.com) and also on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.

For and on behalf of the Board  
Krishna Institute of Medical Sciences Limited

  
Dr. B Bhaskara Rao  
Managing Director  
DIN: 00008985

Hyderabad  
10 February 2022

